Ashutosh Kumar Maurya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashutosh Kumar Maurya has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ashish Kumar Maurya
Bundelkhand University, India
12 shared publications - Jordi Muntane
Universidad de Sevilla, Spain
11 shared publications - V. B. Sameer Kumar
Central University of Kerala, India
9 shared publications - Rajendra Pilankatta
Central University of Kerala, India
4 shared publications - Sr Aiswarjinee
Central University of Kerala, India
3 shared publications - Rajendra Pilankatta
Central University of Kerala, India
2 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by MDPI AG in Preprints.org
From Editing Genes to Orchestrating Networks: CRISPR and the Future of Precision Oncology
The advent of CRISPR-based genome editing has transformed the conceptual framework of oncology—from descriptive molecular profiling to functional genome engineering. By enabling precise, programmable, and multiplex control of cancer-associated genes, CRISPR/Cas systems are reshaping how we model tumorigenesis, predict drug response, and design patient-tailored interventions. This Perspective discusses how CRISPR technologies are redefining precision oncology, the biological and ethical challenges that impede their clinical translation, and emerging strategies that integrate gene editing with immunotherapy, synthetic biology, and systems medicine. We argue that the future of cancer therapy lies not merely in editing genes but in orchestrating the dynamic networks that sustain malignancy.
- 21 April 2026
- Published by MDPI AG in Preprints.org
Open AccessFrom Editing Genes to Orchestrating Networks: CRISPR and the Future of Precision Oncology
The advent of CRISPR-based genome editing has transformed the conceptual framework of oncology—from descriptive molecular profiling to functional genome engineering. By enabling precise, programmable, and multiplex control of cancer-associated genes, CRISPR/Cas systems are reshaping how we model tumorigenesis, predict drug response, and design patient-tailored interventions. This Perspective discusses how CRISPR technologies are redefining precision oncology, the biological and ethical challenges that impede their clinical translation, and emerging strategies that integrate gene editing with immunotherapy, synthetic biology, and systems medicine. We argue that the future of cancer therapy lies not merely in editing genes but in orchestrating the dynamic networks that sustain malignancy.
- Open Access
- 7 November 2025
- Published by MDPI AG in Preprints.org
Cytomegalovirus and Cancer: Revisiting Oncogenic Hypotheses and Therapeutic Perspectives
Human cytomegalovirus (HCMV) has emerged as a potential oncomodulatory agent implicated in the pathogenesis of several cancers, although its precise role in tumorigenesis remains a subject of debate. This review synthesizes five decades of research examining the involvement of HCMV in cancer, with particular focus on molecular mechanisms by which the virus may contribute to tumor progression, including immune evasion, chronic inflammation, and modulation of cell cycle and signaling pathways. Evidence of HCMV detection in malignancies such as glioblastoma, breast, colorectal, and prostate cancers is critically reviewed, alongside ongoing controversies regarding its causal versus passenger role in oncogenesis.The review further explores current and emerging antiviral and immunotherapeutic strategies targeting HCMV within oncological settings, highlighting their potential translational relevance and associated challenges. By reassessing oncogenic hypotheses and therapeutic opportunities, this article aims to provide a comprehensive perspective on the complex interplay between HCMV and cancer biology, and to evaluate its potential as a novel target for cancer prevention and therapy.
- 7 November 2025
- Published by MDPI AG in Preprints.org
Open AccessCytomegalovirus and Cancer: Revisiting Oncogenic Hypotheses and Therapeutic Perspectives
Human cytomegalovirus (HCMV) has emerged as a potential oncomodulatory agent implicated in the pathogenesis of several cancers, although its precise role in tumorigenesis remains a subject of debate. This review synthesizes five decades of research examining the involvement of HCMV in cancer, with particular focus on molecular mechanisms by which the virus may contribute to tumor progression, including immune evasion, chronic inflammation, and modulation of cell cycle and signaling pathways. Evidence of HCMV detection in malignancies such as glioblastoma, breast, colorectal, and prostate cancers is critically reviewed, alongside ongoing controversies regarding its causal versus passenger role in oncogenesis.The review further explores current and emerging antiviral and immunotherapeutic strategies targeting HCMV within oncological settings, highlighting their potential translational relevance and associated challenges. By reassessing oncogenic hypotheses and therapeutic opportunities, this article aims to provide a comprehensive perspective on the complex interplay between HCMV and cancer biology, and to evaluate its potential as a novel target for cancer prevention and therapy.
- Open Access
- 7 November 2025
- Published by MDPI AG in Preprints.org
Translational Nanotechnology in Oncology: Integrating Nanoscale Innovation into Precision Cancer Diagnosis and Therapy
Complexity, heterogeneity, and therapeutic resistance continue to make cancer one of the most challenging diseases to diagnose and treat. Despite substantial advances in molecular biology and immuno-oncology, persistent limitations in early detection, targeted delivery, and therapeutic precision continue to impede effective management. Over the past two decades, nanotechnology has emerged as a transformative frontier, offering innovative strategies for cancer diagnostics and treatment. Engineered nanomaterials—encompassing liposomes, polymeric nanoparticles, quantum dots, and metallic nanostructures—enable precise tumor targeting, enhanced imaging resolution, and controlled therapeutic release.In diagnostics, nanoscale biosensors and imaging probes have markedly improved the sensitivity and specificity of biomarker detection and visualization. In therapeutics, nanocarriers have demonstrated the capacity to minimize systemic toxicity and optimize pharmacokinetics, thereby improving clinical efficacy. Recent developments, including smart and stimuli-responsive nanoplatforms, nanorobotics, and integrated theranostic systems, are redefining the landscape of personalized cancer care. Nonetheless, critical translational challenges remain, particularly regarding large-scale manufacturing, long-term biosafety, and regulatory validation.This review critically examines the evolution of nanotechnology in oncology, synthesizing advances in nanodiagnostics and nanotherapeutics, assessing current clinical progress, and outlining future directions toward achieving precision nanomedicine in cancer diagnosis and therapy.
- 7 November 2025
- Published by MDPI AG in Preprints.org
Open AccessTranslational Nanotechnology in Oncology: Integrating Nanoscale Innovation into Precision Cancer Diagnosis and Therapy
Complexity, heterogeneity, and therapeutic resistance continue to make cancer one of the most challenging diseases to diagnose and treat. Despite substantial advances in molecular biology and immuno-oncology, persistent limitations in early detection, targeted delivery, and therapeutic precision continue to impede effective management. Over the past two decades, nanotechnology has emerged as a transformative frontier, offering innovative strategies for cancer diagnostics and treatment. Engineered nanomaterials—encompassing liposomes, polymeric nanoparticles, quantum dots, and metallic nanostructures—enable precise tumor targeting, enhanced imaging resolution, and controlled therapeutic release.In diagnostics, nanoscale biosensors and imaging probes have markedly improved the sensitivity and specificity of biomarker detection and visualization. In therapeutics, nanocarriers have demonstrated the capacity to minimize systemic toxicity and optimize pharmacokinetics, thereby improving clinical efficacy. Recent developments, including smart and stimuli-responsive nanoplatforms, nanorobotics, and integrated theranostic systems, are redefining the landscape of personalized cancer care. Nonetheless, critical translational challenges remain, particularly regarding large-scale manufacturing, long-term biosafety, and regulatory validation.This review critically examines the evolution of nanotechnology in oncology, synthesizing advances in nanodiagnostics and nanotherapeutics, assessing current clinical progress, and outlining future directions toward achieving precision nanomedicine in cancer diagnosis and therapy.
- Open Access
- 7 November 2025
- Published by MDPI AG in Preprints.org
Molecular Insights into Hepatitis Virus-Induced Hepatocarcinogenesis
Cancer is a multifactorial disease influenced by genetic, epigenetic, and environmental determinants, including biological agents such as oncogenic viruses. Among these, hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV) play pivotal roles in the pathogenesis of hepatocellular carcinoma (HCC)—the predominant form of primary liver cancer and a major contributor to global cancer mortality. Chronic infection with these hepatotropic viruses drives hepatocarcinogenesis through both direct mechanisms, including viral genome integration and oncoprotein expression, and indirect pathways involving persistent inflammation, immune evasion, and oxidative stress.Despite substantial advances in HBV vaccination programs and the development of curative therapies for HCV, the global burden of hepatitis-related liver cancer remains high, driven by underdiagnosis, limited access to care, and the absence of a functional cure for HBV.This review critically examines the molecular and pathogenic mechanisms by which HBV, HCV, and HDV contribute to cancer initiation and progression, and summarizes current therapeutic and preventive strategies. It further highlights emerging research directions and translational challenges that must be addressed to improve prevention, early detection, and treatment of virus-induced hepatocellular carcinoma.
- 7 November 2025
- Published by MDPI AG in Preprints.org
Open AccessMolecular Insights into Hepatitis Virus-Induced Hepatocarcinogenesis
Cancer is a multifactorial disease influenced by genetic, epigenetic, and environmental determinants, including biological agents such as oncogenic viruses. Among these, hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis D virus (HDV) play pivotal roles in the pathogenesis of hepatocellular carcinoma (HCC)—the predominant form of primary liver cancer and a major contributor to global cancer mortality. Chronic infection with these hepatotropic viruses drives hepatocarcinogenesis through both direct mechanisms, including viral genome integration and oncoprotein expression, and indirect pathways involving persistent inflammation, immune evasion, and oxidative stress.Despite substantial advances in HBV vaccination programs and the development of curative therapies for HCV, the global burden of hepatitis-related liver cancer remains high, driven by underdiagnosis, limited access to care, and the absence of a functional cure for HBV.This review critically examines the molecular and pathogenic mechanisms by which HBV, HCV, and HDV contribute to cancer initiation and progression, and summarizes current therapeutic and preventive strategies. It further highlights emerging research directions and translational challenges that must be addressed to improve prevention, early detection, and treatment of virus-induced hepatocellular carcinoma.
- Open Access
- 4 November 2025
- Published by MDPI AG in Preprints.org
Artificial Intelligence in Oncology: Redefining Cancer Diagnosis and Therapy Through Data-Driven Precision
Cancer remains one of the foremost challenges in global health, distinguished by profound biological complexity, heterogeneity, and therapeutic resistance. Over recent decades, oncology has transitioned from broadly cytotoxic regimens toward molecularly targeted and immune-based therapies; nevertheless, substantial clinical gaps persist. The emergence of artificial intelligence (AI) represents a transformative advance in this continuum, offering unprecedented capacity to integrate and interpret multidimensional biomedical data. AI-driven methodologies now play pivotal roles in early cancer detection, histopathological and radiomic assessment, biomarker discovery, and the prediction of therapeutic response. Furthermore, AI is accelerating drug discovery and enabling adaptive, patient-specific treatment strategies that transcend conventional evidence-based paradigms. This review synthesizes recent progress at the interface of AI and oncology, highlighting how machine learning, deep learning, and computational modeling are reshaping diagnostic precision, therapeutic optimization, and clinical decision-making. We also examine persisting challenges, including data heterogeneity, algorithmic transparency, and ethical implementation in real-world settings. Integrating computational intelligence with precision medicine heralds a future of cancer care that is predictive, preventive, and personalized—where human expertise and AI converge to redefine the boundaries of cancer treatment.
- 4 November 2025
- Published by MDPI AG in Preprints.org
Open AccessArtificial Intelligence in Oncology: Redefining Cancer Diagnosis and Therapy Through Data-Driven Precision
Cancer remains one of the foremost challenges in global health, distinguished by profound biological complexity, heterogeneity, and therapeutic resistance. Over recent decades, oncology has transitioned from broadly cytotoxic regimens toward molecularly targeted and immune-based therapies; nevertheless, substantial clinical gaps persist. The emergence of artificial intelligence (AI) represents a transformative advance in this continuum, offering unprecedented capacity to integrate and interpret multidimensional biomedical data. AI-driven methodologies now play pivotal roles in early cancer detection, histopathological and radiomic assessment, biomarker discovery, and the prediction of therapeutic response. Furthermore, AI is accelerating drug discovery and enabling adaptive, patient-specific treatment strategies that transcend conventional evidence-based paradigms. This review synthesizes recent progress at the interface of AI and oncology, highlighting how machine learning, deep learning, and computational modeling are reshaping diagnostic precision, therapeutic optimization, and clinical decision-making. We also examine persisting challenges, including data heterogeneity, algorithmic transparency, and ethical implementation in real-world settings. Integrating computational intelligence with precision medicine heralds a future of cancer care that is predictive, preventive, and personalized—where human expertise and AI converge to redefine the boundaries of cancer treatment.
- Open Access
- 4 November 2025
- Published by MDPI AG in Preprints.org
From Small Molecules to Degraders and AI: Contemporary Trends and Future Directions in Anticancer Drug Discovery
Cancer remains one of the leading causes of death worldwide, demanding continuous innovation in therapeutic strategies. Traditional chemotherapeutic agents, though effective in certain contexts, are limited by systemic toxicity, drug resistance, and non-specific targeting. Over the past two decades, the landscape of anticancer drug discovery has undergone a paradigm shift with the emergence of molecularly targeted agents, immunotherapies, and rational drug design technologies. Advancements in genomics, proteomics, and structural biology have enabled the identification of novel cancer-specific targets, while computational and artificial intelligence (AI)-driven approaches are accelerating lead optimization and predictive modeling of drug efficacy and toxicity. The development of antibody–drug conjugates (ADCs), bispecific antibodies, and targeted protein degraders (PROTACs) represents a new generation of therapies capable of addressing previously “undruggable” targets. Meanwhile, patient-derived organoids, 3D co-culture systems, and high-content screening platforms are refining preclinical evaluation and improving translational success rates. This review summarizes the recent trends in anticancer drug discovery, highlights the integration of computational and experimental pipelines, and explores emerging modalities poised to redefine cancer treatment in the coming decade. The future of anticancer drug discovery lies in combining precision oncology, AI-based design, and systems-level modeling to deliver safer, more effective, and personalized therapies against cancer’s molecular complexity.
- 4 November 2025
- Published by MDPI AG in Preprints.org
Open AccessFrom Small Molecules to Degraders and AI: Contemporary Trends and Future Directions in Anticancer Drug Discovery
Cancer remains one of the leading causes of death worldwide, demanding continuous innovation in therapeutic strategies. Traditional chemotherapeutic agents, though effective in certain contexts, are limited by systemic toxicity, drug resistance, and non-specific targeting. Over the past two decades, the landscape of anticancer drug discovery has undergone a paradigm shift with the emergence of molecularly targeted agents, immunotherapies, and rational drug design technologies. Advancements in genomics, proteomics, and structural biology have enabled the identification of novel cancer-specific targets, while computational and artificial intelligence (AI)-driven approaches are accelerating lead optimization and predictive modeling of drug efficacy and toxicity. The development of antibody–drug conjugates (ADCs), bispecific antibodies, and targeted protein degraders (PROTACs) represents a new generation of therapies capable of addressing previously “undruggable” targets. Meanwhile, patient-derived organoids, 3D co-culture systems, and high-content screening platforms are refining preclinical evaluation and improving translational success rates. This review summarizes the recent trends in anticancer drug discovery, highlights the integration of computational and experimental pipelines, and explores emerging modalities poised to redefine cancer treatment in the coming decade. The future of anticancer drug discovery lies in combining precision oncology, AI-based design, and systems-level modeling to deliver safer, more effective, and personalized therapies against cancer’s molecular complexity.
- Open Access
- 27 October 2025
- Published by MDPI AG in Preprints.org
Precision Oncology in the CRISPR Era: Applications and Future Horizons in Cancer Therapy
The advent of CRISPR/Cas9 genome editing technology has revolutionized cancer research by enabling precise, efficient, and versatile manipulation of genetic sequences implicated in oncogenesis and tumor progression. This review highlights the pivotal role of CRISPR/Cas9 in unraveling cancer biology, developing innovative therapeutic strategies, and advancing personalized medicine. Conventional cancer treatments such as chemotherapy, radiotherapy, and surgery, while effective, suffer from significant limitations including non-specific toxicity and resistance, necessitating the exploration of novel targeted approaches. CRISPR/Cas9 offers unprecedented capabilities for targeted gene editing, including correction of oncogenic mutations, silencing of tumor-promoting genes, and restoration of tumor suppressor function. Additionally, it facilitates the generation of patient-specific tumor models such as organoids and xenografts that can guide therapeutic decision-making. Current preclinical studies and early-phase clinical trials demonstrate the feasibility and promise of CRISPR-based therapies, although challenges such as off-target effects, efficient delivery, and ethical considerations must be carefully addressed. Emerging technologies including base and prime editing, improved delivery vectors, and RNA-targeting Cas enzymes are expanding the CRISPR toolbox for cancer therapeutics. Furthermore, novel applications targeting the tumor microenvironment and microbiome are gaining traction. In summary, CRISPR/Cas9 represents a transformative platform driving the future of precision oncology, offering hope for more effective, tailored cancer treatments.
- 27 October 2025
- Published by MDPI AG in Preprints.org
Open AccessPrecision Oncology in the CRISPR Era: Applications and Future Horizons in Cancer Therapy
The advent of CRISPR/Cas9 genome editing technology has revolutionized cancer research by enabling precise, efficient, and versatile manipulation of genetic sequences implicated in oncogenesis and tumor progression. This review highlights the pivotal role of CRISPR/Cas9 in unraveling cancer biology, developing innovative therapeutic strategies, and advancing personalized medicine. Conventional cancer treatments such as chemotherapy, radiotherapy, and surgery, while effective, suffer from significant limitations including non-specific toxicity and resistance, necessitating the exploration of novel targeted approaches. CRISPR/Cas9 offers unprecedented capabilities for targeted gene editing, including correction of oncogenic mutations, silencing of tumor-promoting genes, and restoration of tumor suppressor function. Additionally, it facilitates the generation of patient-specific tumor models such as organoids and xenografts that can guide therapeutic decision-making. Current preclinical studies and early-phase clinical trials demonstrate the feasibility and promise of CRISPR-based therapies, although challenges such as off-target effects, efficient delivery, and ethical considerations must be carefully addressed. Emerging technologies including base and prime editing, improved delivery vectors, and RNA-targeting Cas enzymes are expanding the CRISPR toolbox for cancer therapeutics. Furthermore, novel applications targeting the tumor microenvironment and microbiome are gaining traction. In summary, CRISPR/Cas9 represents a transformative platform driving the future of precision oncology, offering hope for more effective, tailored cancer treatments.
- Open Access
- 22 October 2025
- Published by MDPI AG in Preprints.org
The Oncology of Liver Cancer: Integrating Molecular Insights with Therapeutic Innovation
Liver cancer, predominantly hepatocellular carcinoma (HCC), represents a major global health challenge due to its rising incidence and high mortality rates. This review provides a comprehensive overview of liver cancer pathogenesis, emphasizing the complex interplay of viral infections, metabolic disorders, and genetic alterations driving tumor development. We detail the classification of primary liver cancers and highlight the distinctive molecular and clinical features of HCC and intrahepatic cholangiocarcinoma. Advances in research have led to improved understanding of tumor biology and immune microenvironment, fostering the emergence of targeted therapies and immunotherapies. From the historic reliance on surgical resection and sorafenib to the recent approval of immunotherapy combinations such as atezolizumab plus bevacizumab, therapeutic strategies have evolved substantially, offering improved patient outcomes. Despite these advances, challenges remain in early diagnosis, treatment resistance, and biomarker development. Future directions focus on personalized medicine, novel combination therapies, and global accessibility to enhance survival and quality of life for liver cancer patients. This review synthesizes current knowledge and future perspectives, aiming to inform ongoing efforts to combat this formidable malignancy.
- 22 October 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Oncology of Liver Cancer: Integrating Molecular Insights with Therapeutic Innovation
Liver cancer, predominantly hepatocellular carcinoma (HCC), represents a major global health challenge due to its rising incidence and high mortality rates. This review provides a comprehensive overview of liver cancer pathogenesis, emphasizing the complex interplay of viral infections, metabolic disorders, and genetic alterations driving tumor development. We detail the classification of primary liver cancers and highlight the distinctive molecular and clinical features of HCC and intrahepatic cholangiocarcinoma. Advances in research have led to improved understanding of tumor biology and immune microenvironment, fostering the emergence of targeted therapies and immunotherapies. From the historic reliance on surgical resection and sorafenib to the recent approval of immunotherapy combinations such as atezolizumab plus bevacizumab, therapeutic strategies have evolved substantially, offering improved patient outcomes. Despite these advances, challenges remain in early diagnosis, treatment resistance, and biomarker development. Future directions focus on personalized medicine, novel combination therapies, and global accessibility to enhance survival and quality of life for liver cancer patients. This review synthesizes current knowledge and future perspectives, aiming to inform ongoing efforts to combat this formidable malignancy.
- Open Access
- 21 October 2025
- Published by MDPI AG in Preprints.org
Next‐Generation Cancer Therapeutics: Revolutionizing Treatment with Precision Medicine and Immunotherapy
Cancer remains one of the leading causes of death worldwide, with traditional therapies like surgery, chemotherapy, and radiation being limited by toxicity and resistance. Recent breakthroughs in antibody-mediated therapies, precision medicine, and immunotherapies are reshaping the cancer treatment landscape. Monoclonal antibodies (mAbs), immune checkpoint inhibitors, and chimeric antigen receptor T-cell (CAR-T) therapies have proven to be highly effective, offering more targeted, less toxic alternatives to traditional treatments. Alongside these innovations, the integration of genomic profiling and next-generation sequencing (NGS) has paved the way for precision oncology, where therapies are tailored to the unique genetic makeup of a patient’s cancer. However, challenges such as tumor heterogeneity, therapy resistance, and immunotoxicity persist. This review discusses the mechanisms, clinical successes, and challenges associated with antibody-mediated therapies and precision medicine, as well as emerging treatment modalities. We also highlight the role of artificial intelligence (AI) in accelerating cancer research and improving therapeutic outcomes.
- 21 October 2025
- Published by MDPI AG in Preprints.org
Open AccessNext‐Generation Cancer Therapeutics: Revolutionizing Treatment with Precision Medicine and Immunotherapy
Cancer remains one of the leading causes of death worldwide, with traditional therapies like surgery, chemotherapy, and radiation being limited by toxicity and resistance. Recent breakthroughs in antibody-mediated therapies, precision medicine, and immunotherapies are reshaping the cancer treatment landscape. Monoclonal antibodies (mAbs), immune checkpoint inhibitors, and chimeric antigen receptor T-cell (CAR-T) therapies have proven to be highly effective, offering more targeted, less toxic alternatives to traditional treatments. Alongside these innovations, the integration of genomic profiling and next-generation sequencing (NGS) has paved the way for precision oncology, where therapies are tailored to the unique genetic makeup of a patient’s cancer. However, challenges such as tumor heterogeneity, therapy resistance, and immunotoxicity persist. This review discusses the mechanisms, clinical successes, and challenges associated with antibody-mediated therapies and precision medicine, as well as emerging treatment modalities. We also highlight the role of artificial intelligence (AI) in accelerating cancer research and improving therapeutic outcomes.
- Open Access
- 21 October 2025
- Published by MDPI AG in Preprints.org
Exosomal MicroRNAs in Cancer: Mechanisms, Clinical Applications, and Challenges in Biomarker Discovery
Exosomal microRNAs (miRNAs) have emerged as promising candidates for cancer biomarker discovery due to their unique properties as stable, non-invasive, and informative molecules in body fluids. These small, membrane-bound vesicles play critical roles in intercellular communication by transferring miRNAs, which regulate gene expression and influence various biological processes, including cancer progression, metastasis, and drug resistance. Recent advancements in exosome isolation and miRNA profiling technologies have unveiled their potential for early cancer detection, prognosis, and therapeutic monitoring. Exosomal miRNAs offer several advantages over traditional biomarkers, including ease of detection in liquid biopsies (e.g., blood, urine), the ability to reflect the molecular landscape of tumors, and their association with both primary and metastatic cancer sites. However, despite the growing body of evidence supporting their utility, challenges such as standardization of isolation methods, variability in miRNA expression across cancer types, and the need for large-scale clinical validation remain significant barriers to clinical translation. This review highlights the biological mechanisms by which exosomal miRNAs influence cancer biology, their clinical applications in cancer diagnosis and therapy, and the technological advancements driving their profiling. Additionally, we discuss the current challenges and future directions for harnessing exosomal miRNAs in precision oncology.
- 21 October 2025
- Published by MDPI AG in Preprints.org
Open AccessExosomal MicroRNAs in Cancer: Mechanisms, Clinical Applications, and Challenges in Biomarker Discovery
Exosomal microRNAs (miRNAs) have emerged as promising candidates for cancer biomarker discovery due to their unique properties as stable, non-invasive, and informative molecules in body fluids. These small, membrane-bound vesicles play critical roles in intercellular communication by transferring miRNAs, which regulate gene expression and influence various biological processes, including cancer progression, metastasis, and drug resistance. Recent advancements in exosome isolation and miRNA profiling technologies have unveiled their potential for early cancer detection, prognosis, and therapeutic monitoring. Exosomal miRNAs offer several advantages over traditional biomarkers, including ease of detection in liquid biopsies (e.g., blood, urine), the ability to reflect the molecular landscape of tumors, and their association with both primary and metastatic cancer sites. However, despite the growing body of evidence supporting their utility, challenges such as standardization of isolation methods, variability in miRNA expression across cancer types, and the need for large-scale clinical validation remain significant barriers to clinical translation. This review highlights the biological mechanisms by which exosomal miRNAs influence cancer biology, their clinical applications in cancer diagnosis and therapy, and the technological advancements driving their profiling. Additionally, we discuss the current challenges and future directions for harnessing exosomal miRNAs in precision oncology.